A Study to Evaluate the Efficacy and Safety of Pregabalin (Lyrica) for the Treatment of Nerve Pain

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

112 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-11-30

Study Completion Date

2005-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the efficacy and safety of Lyrica in Indian patients with nerve pain

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study To Evaluate Efficacy, Safety And Tolerability Of Lyrica In Patients With Painful Diabetic Peripheral Neuropathy

NCT01332149

Diabetic Neuropathy, Painful

COMPLETED PHASE3

Symptomatic Treatment Of Patients With Neuropathic Pain With LYRICA

NCT00843284

Neuropathic Pain

COMPLETED

Efficacy Study Measuring the Impact of Pregabalin on Peripheral Neuropathic Pain.

NCT00219544

Neuropathic Pain

COMPLETED PHASE3

A Post Marketing Surveillance Study On Pregabalin (Lyrica) On Efficacy, Safety And Tolerability Of Pregabalin

NCT00892008

Neuropathic Pain

COMPLETED

Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy

NCT01057693

Diabetic Neuropathy, Painful

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neuralgia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Group Type EXPERIMENTAL

Pregabalin (Lyrica)

Intervention Type DRUG

Oral pregabalin (Lyrica) capsules, initial dose of 75 mg twice daily, which could be increased to 300 mg twice daily at the discretion of the investigator. Patients were treated for up to 21 days.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pregabalin (Lyrica)

Oral pregabalin (Lyrica) capsules, initial dose of 75 mg twice daily, which could be increased to 300 mg twice daily at the discretion of the investigator. Patients were treated for up to 21 days.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Peripheral neuropathic pain
* Score of at least 40 mm on the VAS of the SF-MPQ at screening and baseline
* Completion of at least 4 daily pain diary entries with an average daily pain score of at least 4 over the 7 days prior to baseline